Pazan, Farhad
Burkhardt, Heinrich
Frohnhofen, Helmut
Weiss, Christel
Throm, Christina
Kuhn-Thiel, Alexandra
Wehling, Martin
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (WE 1184/15-1, FR2997/2-1)
Article History
First Online: 21 December 2018
Compliance with Ethical Standards
:
: The study was funded by the DFG, German Research Foundation (WE 1184/15-1 to Martin Wehling and Heinrich Burkhardt, FR2997/2-1 to Helmut Frohnhofen).
: Martin Wehling was employed by AstraZeneca R&D, Mölndal, as the director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire, and LEO Pharma. Helmut Frohnhofen received lecturing and consulting fees from Amgen. Farhad Pazan, Heinrich Burkhardt, Christina Throm, Alexandra Kuhn-Thiel, and Christel Weiss have no conflicts of interest that are directly relevant to the contents of this study.
: The study was approved by the Ethics Committee of the Medical Faculty Mannheim, Heidelberg University and the Ethics Committee of the University of Witten-Herdecke.
: Informed consent was obtained from all individual participants included in the study.